Hotgen Biotech Introduces Chikungunya Rapid Test to Strengthen Global Health Response

Recently, Hotgen Biotech successfully developed the Chikungunya IgG/IgM Rapid Test (Colloidal Gold). This product allows for quick testing of IgG and IgM antibodies to the Chikungunya virus (CHIKV) in blood samples in just 15 minutes, helping to diagnose the disease early and control outbreaks quickly.

On July 25, 2025, the World Health Organization (WHO) issued a warning that the Chikungunya virus is spreading in multiple regions worldwide, with 119 countries reporting cases and an estimated 5.5 million people at risk of infection. Chikungunya is a mosquito-borne viral disease, with key symptoms including sudden high fever and severe joint pain. As the virus spreads globally, rapid and accessible diagnostics are critical for timely prevention and control.

Hotgen Biotech’s portfolio of rapid diagnostics for mosquito-borne diseases includes Dengue NS1 Ag/Ab Combo, Dengue IgM/IgG, Dengue NS1 Antigen, Malaria Pf/Pan Antigen, and Chikungunya IgG/IgM. Several of these products have received CE certificate and are available for the international market, supporting global disease surveillance and response efforts.

With ongoing investment in global infectious disease prevention, Hotgen is committed to providing efficient and reliable tools for outbreak management—contributing to the fight against mosquito-borne epidemics, especially in resource-limited regions.